Use the pattern recognition workspace to apply Hanging Man recognition and other studies to Compass Therapeutics. This view tracks pattern recognition signals tied to momentum and continuation to support structured performance interpretation without implying advice.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was eleven with a total number of output elements of fifty. The function did not return any valid pattern recognition events for the selected time horizon. The Hanging Man pattern describes Compass Therapeutics bearish reversal trend.
Compass Therapeutics Technical Analysis Modules
Most technical analysis of Compass Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Compass from various momentum indicators to cycle indicators. When you analyze Compass charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. A high-level view of Compass Therapeutics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 4.73. Compass Therapeutics has market cap of 990.69 M, ROE of -41.29%.
Methodology
Unless otherwise specified, financial data for Compass Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Compass (USA Stocks:CMPX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Compass Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Compass Therapeutics is covered by 16 analysts. 8 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include J.P. Morgan, Stifel, BMO Capital Markets, Oppenheimer & Co., Citigroup, RBC Capital Markets, Wells Fargo Securities, Evercore ISI, among others. Updates may occur throughout the day.
Be your own money manager
Tracking Compass Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
Reviewing Compass Therapeutics commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Compass Therapeutics Stock. Below are reports that help frame Compass Therapeutics Stock in context:
Compass Therapeutics has market cap of 990.69 M, ROE of -41.29%. See Trending Equities for portfolio-level analysis. This suggests a position in Compass Therapeutics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Learn how to buy and trade Compass Stock using our step-by-step How to Buy Compass Therapeutics guide.Analysis related to Compass Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Earnings Share
-0.45
Return On Assets
-0.25
Return On Equity
-0.41
Understanding Compass Therapeutics includes distinguishing between market value and book value, where book value reflects Compass accounting equity. Compass Therapeutics' market capitalization is 990.69 M. With a P/B ratio of 4.73, the market values Compass Therapeutics well above its book equity. Enterprise value stands at 780.66 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Compass Therapeutics differs from its quoted price, since each reflects a different lens. For Compass Therapeutics, key inputs include a P/B ratio of 4.73, and ROE of -41.29%. By contrast, market price reflects the level where buyers and sellers transact.